Feline Diabetes and Pre-Diabetes (Obesity)

Treatable with OKV-119

As more pet cats live primarily indoors, the prevalence of inactivity is increasing, resulting in rapidly increasing rates of obese/overweight felines currently at 59% (56 million clinically obese cats live in the United States alone) 1. Left untreated, obesity in cats increases the risk of diabetes, heart disease, kidney disease, and arthritis/joint pain. Diet alteration alone is typically not sufficient treatment, and indoor cats have few options for exercise.

Along with the obesity trend, feline diabetes is on the rise. However, unlike humans, the only approved treatments available to cats are diet adjustment and insulin shots. 20% to 48% of diabetic cats are euthanized within a year, often because of sub-optimal treatment options 2. As cats (and pets in general) become more socially integrated into human households, there is increased demand and willingness to pay for feline health care. Desperate pet owners and veterinarians often resort to using expensive, difficult to administer, and untested human medications.

1 2018 National Pet Obesity Survey Results from Association for Pet Obesity Prevention
2 O’neill, 2016 and Niessen, 2017

Problems With Current Treatment


  • No Treatments, Yes Market

    People are spending more on pet treatments than ever ($70 billion in 2017, with a 6.2% CAGR), yet many human treatments have not been translated to pets, despite having similar diseases.

  • Dosing Is Difficult

    Finding, subduing, and dosing pet cats frequently is difficult for the owner and stressful for the pet.

  • Non-Treatment Is Very Painful

    Felines left untreated often develop diabetes, joint disease and/or arthritis, heart disease, and/or kidney disease.

Ref: Wright, E. Credit Suisse Animal Health Update - July 24, 2018

How We Solve It

Only One Implant Is Necessary

  • Small device, simple insertion

    NanoPortal implantation can be performed in a quick, outpatient procedure.

  • Extended duration

    NanoPortal is being designed to last for durations of 6 months to 1 year in felines.

  • Ensured compliance

    Implantation ensures continuous dosing for the duration of the treatment.

Human Type II Diabetes
Non-Alcoholic Steatohepatitis (NASH)